PDCD1 and neoplasm: By adopting anti-PD-1 CAR-T cells in NSG mice, mouse CAR-T cells showed enhanced antitumor reactivity, and the amplification effect of CAR-T cells was enhanced [32], promoting tumor regression and reducing the incidence of adverse reactions [47, 48].